Kelly Hsu's questions to Verastem Inc (VSTM) leadership • Q2 2025
Question
Anshi, on behalf of Kelly Hsu, inquired about the key performance indicators Verastem is tracking to measure the launch success of AvmapKefaxin Jakobak and how those indicators might predict momentum in the second half of the year.
Answer
President and CEO Dan Paterson explained that it's still early but they are beginning to track broader data now that specialty distributors and GPOs are onboarded. COO Matthew Ros elaborated that future reporting on performance will be anchored against their three strategic imperatives: engagement with the healthcare community, ensuring seamless patient access, and working with the patient population.